Xconomy: Aerie Pharma Eyes $58M IPO For Glaucoma Drug Push
Aerie Pharma slips after announcing eye disease trial failed to meet primary endpoints | Seeking Alpha
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Pharmaceuticals Inc 2021 Current Report 8-K
Durham-based Aerie Pharma sees positive study results for eye pressure drug | WRAL TechWire
Investor Relations | Aerie Pharmaceuticals, Inc
Aerie Pharma appoints Richard Rubino as CFO
Research & Development | Aerie Pharmaceuticals, Inc.
AeriePharma (@AeriePharma) | Twitter
Compliance Program | Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc.
Aerie Pharma (AERI) Falls on Glaucoma Eye Drop Safety Concerns - TheStreet
Working at Aerie Pharmaceuticals | Glassdoor
Aerie Pharmaceuticals Employees, Location, Careers | LinkedIn
Aerie Pharma on go with mid-stage study of eye drop for dry eye (NASDAQ:AERI) | Seeking Alpha
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Pharmaceuticals and Ramot at Tel Aviv University Enter Research Collaboration | Business Wire
Analysts Offer Insights on Healthcare Companies: Cooper Co (NYSE: COO) and Aerie Pharma (NASDAQ: AERI) - Markets
Aerie Pharmaceuticals (Nasdaq: AERI) acquires Spanish company Avizorex Pharma - Triangle Business Journal
Aerie Pharma leaps on positive Ph III efficacy results for Rhopressa
Rx Item-RHOPRESSA 0.02 % O/S 2.5 ML netarsudil mesylate DROPS BY AERIE PHARMA
Aerie Pharmaceuticals, Inc (AERI) July 7, 2021 Stock Price, Analysis & Forecast | List23: Latest U.S. News & Breaking World News
Aerie Pharma Re-Ups In Irvine, CEO Departs | Orange County Business Journal
AERIE PHARMACEUTICALS, INC. - Aerie Pharmaceuticals, Inc. Trademark Registration
Casey Kopczynski - Chief Scientific Officer and Founder - Aerie Pharmaceuticals, Inc | LinkedIn
